Results 171 to 180 of about 4,227,388 (391)

Designer Drugs: Effects and Management; A Critical Review

, 2017
Ananda Kudari
openalex   +1 more source

BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights

, 2021
Simona Zaami, Silvia Graziano, Roberta Tittarelli, Renata Beck, Enrico Marinelli   +4 more
openalex   +2 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Designer drugs and sexual dysfunction

, 2015
Mátyás Benyó
openalex   +1 more source

Amphetamine in illegally produced phenylethylamine –intentional action or failed synthesis of a designer drug. Analysis of evidence material by LC/MS (APCI)and GC/MS (EI) methods [PDF]

, 2015
Agnieszka Chłopaś‐Konowałek, Krzysztof Bańka, Grzegorz Buszewicz   +2 more
openalex   +1 more source

Conclusion [PDF]

, 2012
Concluding analysis of the challenges of regulating ...
Elliston, S., McLean, S.
core  

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Cooperative research and development opportunities with the National Cancer Institute [PDF]

The Office of Technology Development (OTD) of the National Cancer Institute (NCI) is responsible for negotiating Cooperative Research and Development Agreements (CRADAs), whereby the knowledge resulting from NCI investigators' government-sponsored ...
Sybert, Kathleen
core   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Characteristic Trends in Prevalence and Use of New Synthetic "Designer" Drugs over the Territory of the Republic of Bashkortostan. [PDF]

, 2016
Azat R. Asadullin, V. L. Yuldashev, Elena Kh. Galeeva, Elvina A. Achmetova, Ivan V. Nikolaev   +4 more
openalex